Please provide your email address to receive an email when new articles are posted on . The combination treatment decreased fat in the submental area and increased volume in the jawline. Submental ...

Dublin, Feb. 05, 2025 (GLOBE NEWSWIRE) -- The "Submental Fat Treatment Market by Type, by Product, by End-user, and by Region" report has been added to ResearchAndMarkets.com's offering. The global ...

REROVOT, Israel, March 4, 2025 /PRNewswire/ -- Raziel Therapeutics, a pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market, announces phase 3 ...

The FDA announced today it has approved Kybella, also known as ATX-101, for the treatment of moderate-to-severe submental fat in adults. Kybella (deoxycholic acid, Kythera Biopharmaceuticals) is not ...

Alexandria, VA — Liposuction is a novel and minimally invasive procedure for treating persistent submental lymphedema in patients with previous head and neck cancer, according to an article published ...

MIAMI BEACH, Florida — Deoxycholic acid (ATX-101, Kythera Biopharmaceuticals) improves the appearance of unwanted fat under the chin, results of an open-label phase 3 clinical trial suggest. The ...

I sat back, exposing the vulnerable area under my chin, bracing myself for the pinch of the needle. I clutched an ice pack, ready to apply it, and looked around as my heart raced. I was about to have ...

Deoxycholic acid, an endogenously produced bile acid, has emerged as a pioneering non‐surgical treatment for reducing submental fat. By selectively inducing adipocytolysis—the breakdown of fat ...

A new injection drug approved yesterday by the FDA offers the first non-surgical treatment for double chins—more accurately, moderate-to-severe “submental” fat below the chin. Kythera ...

The Centers for Medicare and Medicaid Services report that US healthcare expenditures grew by 4.6% to US$ 3.8 trillion in 2019, or US$ 11,582 per person, and accounted for 17.7% of GDP. Also, the ...